Core Viewpoint - The company has reported significant growth in its third-quarter performance, with a focus on enhancing its core business and expanding into international markets, while also undergoing governance changes by eliminating the supervisory board [2][3][26]. Financial Performance - The company's third-quarter revenue increased by 17.71% compared to the previous quarter [2]. - New orders increased by 29.37% year-on-year, with a notable 30.71% growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA) [2]. - The total order amount on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [2]. Market Expansion - The company has established diverse marketing channels to enhance its international market presence, resulting in a significant increase in new orders from overseas markets [3]. - The focus on innovative drug development includes high-potential areas such as CAR-T, small nucleic acids, and multi-specific antibodies, with substantial growth in contract amounts for these innovative categories [3]. Governance Changes - The company plans to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with the new Company Law effective from July 1, 2024 [26][27]. - Amendments to the company's articles of association will reflect this governance change and other necessary updates [28][29].

Core Insights - The company reported a revenue of 571 million yuan for the first three quarters of 2025, representing a year-on-year decline of 35.33% [1] - The net profit attributable to the company was -14.79 million yuan, a year-on-year decrease of 111.14% [1] Business Performance - The company indicated that the order scale and business quality improved simultaneously, with a steady increase in order reserves [1] - New signed orders increased by 29.37% year-on-year, highlighting growth in the company's core business [1] - The number of new drug clinical trial applications (IND) and new drug marketing applications (NDA) signed increased by 30.71% year-on-year, with contract amounts rising by 23.06% [1] Future Outlook - As of the end of the reporting period, the amount of orders on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [1]

Core Insights - The company reported a revenue of 571 million yuan for the first three quarters of 2025, with a third-quarter revenue of 195 million yuan, reflecting a quarter-on-quarter growth of 17.71% [1] - New signed orders increased by 29.37% year-on-year, showcasing the strength of the core business, particularly in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which saw a combined increase of 30.71% in order numbers and a 23.06% rise in contract value [1] - The company is positioned in a high-growth cycle within the global CRO industry, leveraging its technological advantages and comprehensive service capabilities to meet high-end demands [1] Business Performance - The company has shown signs of recovery in its operations, with a nearly 20% increase in the amount of orders on hand compared to the end of 2024, laying a solid foundation for future operations [2] - The company has expanded its overseas market presence through diverse marketing channels, resulting in a significant year-on-year increase in new signed orders from international markets, enhancing its brand recognition and influence [2] Innovation and R&D Focus - The company continues to focus on high-potential areas in innovative drug development, particularly in emerging categories such as in vivo CAR-T, small nucleic acids, bispecific/multispecific antibodies, and radioactive drugs, with significant year-on-year growth in contract values for these innovative products [2]

Core Viewpoint - Yinos has established itself as a leading player in the preclinical safety evaluation sector in China, with a strong backing from state-owned enterprises and a professional core team, and is set to go public on the Shanghai Stock Exchange in September 2024 [1] Business Performance - In Q3 2025, Yinos achieved a revenue of 571 million yuan, ranking 18th among 29 companies in the industry, while the industry leader, WuXi AppTec, reported revenue of 32.857 billion yuan [2] - The company's non-clinical revenue was 361 million yuan, accounting for 96.31% of total revenue, while clinical revenue was 12.8517 million yuan, making up 3.42% [2] - The net profit for the same period was 4.6477 million yuan, placing it 25th in the industry, with the industry average net profit being 58.5 million yuan [2] Financial Ratios - As of Q3 2025, Yinos had a debt-to-asset ratio of 25.17%, which is higher than the industry average of 22.79% [3] - The gross profit margin for Yinos was 28.34%, lower than the industry average of 37.70% [3] Executive Compensation - The total compensation for the president, Chang Yan, was 1.7827 million yuan in 2024, a decrease of 472,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 9.97% to 4,849, while the average number of shares held per shareholder increased by 257.28% to 18,700 shares [5] Market Outlook - According to Dongfang Securities, Yinos experienced a decline in performance in H1 2025 due to reduced domestic investment and slower market demand, but new orders continued to grow, with a 7.4% increase in new orders totaling 530 million yuan [6] - The company has made significant progress in overseas markets, with overseas revenue reaching 15.07 million yuan, a year-on-year increase of 160.4% [6] - Yinos is positioned as a leading player in the domestic CRO industry, with a strong growth outlook supported by its strategic initiatives and resource backing [6]

证券代码：688710 证券简称：益诺思 公告编号：2025-036 上海益诺思生物技术股份有限公司 关于取消监事会暨修订《公司章程》及部分公司治理 制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 在公司股东大会审议通过上述事项前，公司第三届监事会及监事仍将严格按 照《公司法》《公司章程》 等相关法律法规及规范性文件的要求继续履行职责， 维护公司及全体股东的合法利益。公司对第三届监事会全体监事为公司发展做出 的贡献表示衷心的感谢。 公司结合实际情况拟取消监事会，由董事会审计委员会行使《公司法》规定 的监事会的职权，公司《监事会议事规则》相应废止，公司章程及各项治理制度 中涉及监事会、监事相关的规定不再适用。公司第三届监事会监事将自公司股东 大会审议通过取消监事会及修订《公司章程》事项之日起解除职位。 上海益诺思生物技术股份有限公司（以下简称"公司"）于2025年10月29 日召开第三届董事会第二十次会议及第三届监事会第十三次会议，审议通过了 《关于修订<公司章程>暨取消监事会并废止<监事会议事规则>的议案》等相 ...

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2025 年第四次临时股东大会 会议资料 二〇二五年十月 上海益诺思生物技术股份有限公司 2025 年第四次临时股东大会会议资料 2025 年第四次临时股东大会会议资料目录 | 2025年第四次临时股东大会须知 3 | | --- | | 2025年第四次临时股东大会会议议程 5 | | 议案一：关于修订《公司章程》暨取消监事会并废止《监事会议事规则》的议案 6 | | 议案二：关于修订《股东会议事规则》《董事会议事规则》等部分公司治理制度的议案 9 | 上海益诺思生物技术股份有限公司 2025 年第四次临时股东大会会议资料 2025年第四次临时股东大会须知 根据中国证券监督管理委员会《上市公司股东会规则》和《公司章程》的 有关规定，为确保公司股东大会顺利召开，特制定大会须知如下，望出席股东 大会的全体人员遵守执行： 一、公司董事会办公室具体负责大会有关程序、资料相关的事宜。 二、股东大会期间，全体出席人员应以维护股东的合法利益、确保大会正 常秩序和议事效率为原则，认真履行法定职责。 三、在大会主持人宣布现场出席会议的股东和股东代理人人 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-037 召开日期时间：2025 年 11 月 28 日 14 点 30 分 召开地点：中国（上海）自由贸易试验区郭守敬路 199 号 105 会议室 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 上海益诺思生物技术股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票起止时间：自2025 年 11 月 28 日 至2025 年 11 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 股东大会召开日期：2025年11月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （一） 股东大会类型和届次 2025年第四次临时股东大会 （二） 股东大会召集人：董事会 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-035 上海益诺思生物技术股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海益诺思生物技术股份有限公司（以下简称"公司"）第三届监事会第十 三次会议于2025年10月29日在公司会议室以现场结合通讯的方式召开，本次会议 应出席监事3人，实际出席会议监事3人。会议由公司监事会主席高莉女士主持。 此次会议的通知、召集、召开、表决程序符合《中华人民共和国公司法》等 法律、法规、规范性文件及《公司章程》的规定，会议决议合法有效。 监事会认为：公司《2025年第三季度报告》的编制和审议程序符合法律、法 规和《公司章程》的规定。所包含的信息能从各个方面真实地反映出公司2025 年第三季度的经营管理和财务状况等事项。监事会及全体监事保证公司《2025 年第三季度报告》所披露的信息真实、准确、完整，所载资料不存在任何虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥195,459,510.06, a decrease of 29.39% compared to the same period last year[4] - The total profit for the quarter was ¥1,175,106.85, reflecting a significant decline of 97.19% year-over-year[4] - The net profit attributable to shareholders was ¥401,474.08, down 98.92% compared to the previous year[4] - Operating revenue decreased by 35.33% year-to-date due to intense market competition and declining sales order prices[11] - Total profit for the current reporting period fell by 97.19%, and year-to-date total profit decreased by 98.83%[11] - Net profit attributable to shareholders for the current period dropped by 98.92%, with a year-to-date decline of 111.14%[11] - Basic earnings per share for the current period decreased by 99.11%, and year-to-date by 108.67% due to the decline in net profit[12] - Operating profit for the first three quarters of 2025 was ¥4,581,673.96, a significant decline from ¥146,651,397.15 in 2024[24] - Net profit for the first three quarters of 2025 was ¥4,647,746.93, compared to ¥124,414,745.60 in the same period of 2024, reflecting a decrease of 96.3%[24] Cash Flow - The company reported a cash flow from operating activities of ¥21,935,800.96 for the year-to-date period[4] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 21,935,800.96, while in 2024, it was a negative CNY 99,312,083.69, indicating a significant turnaround[28] - The cash inflow from operating activities for the first three quarters of 2025 was CNY 698,302,735.20, compared to CNY 603,333,954.07 in the same period of 2024, representing an increase of approximately 15.7%[28] - The total cash inflow from operating activities included CNY 46,873,854.46 from other operating-related cash in 2025, compared to CNY 24,817,456.27 in 2024, marking an increase of approximately 88.8%[28] - The total cash outflow from operating activities in the first three quarters of 2025 was CNY 676,366,934.24, slightly lower than CNY 702,646,037.76 in 2024[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,174,127,821.50, a decrease of 1.41% from the end of the previous year[5] - The total assets as of the end of the reporting period were ¥3,174,127,821.50, slightly down from ¥3,219,540,808.87 at the end of the previous period[19] - Total liabilities decreased to ¥799,083,534.90 from ¥817,421,758.29, indicating a reduction of 2.7%[19] - The total equity attributable to shareholders decreased to ¥2,337,060,148.09 from ¥2,391,927,683.26, a decline of 2.3%[19] Research and Development - R&D investment totaled ¥10,712,513.21 in Q3, a decrease of 21.77% year-over-year, representing 5.48% of operating revenue[5] - The company is focusing on high-potential areas in drug development, including CAR-T and multi-specific antibodies, with significant growth in contract amounts for these innovative products[7] - The company aims to enhance service quality and strengthen technological R&D to improve operational resilience and risk management capabilities[7] Shareholder Information - The number of common shareholders at the end of the reporting period was 4,849[14] - The largest shareholder, China Pharmaceutical Industrial Research Institute, holds 20.62% of the shares, totaling 29,076,360 shares[14] Earnings Per Share - The company reported a basic and diluted earnings per share of -¥0.10 for the first three quarters of 2025, compared to ¥1.21 in the same period of 2024[25] Other Financial Metrics - The weighted average return on net assets decreased by 1.89 percentage points for the current period and by 8.17 percentage points year-to-date[12] - The company has incurred a credit impairment loss of -¥3,742,224.63, which is a slight improvement from -¥4,502,831.59 in the previous year[24] - The cash inflow from investment activities in the first three quarters of 2025 was CNY 112,182,735.82, compared to CNY 298,900.00 in 2024, showing a substantial increase[29] - The net cash flow from investment activities was negative CNY 85,722,356.10 in 2025, compared to negative CNY 187,163,922.24 in 2024, indicating an improvement[29] - The cash inflow from financing activities in the first three quarters of 2025 was CNY 7,600,000.00, significantly lower than CNY 627,744,415.22 in 2024[29] - The net cash flow from financing activities was negative CNY 51,179,054.70 in 2025, contrasting with a positive CNY 612,588,055.26 in 2024, reflecting a decline in financing[29] - The cash and cash equivalents at the end of the third quarter of 2025 amounted to CNY 1,192,039,873.02, down from CNY 1,483,831,309.18 at the end of 2024[29] Accounting Standards - The company did not apply new accounting standards for the first time in 2025, as stated in the announcement[30]

上海益诺思生物技术股份有限公司 募集资金使用管理办法 第一章 总则 第一条 为规范上海益诺思生物技术股份有限公司（以下简称 "公司"）募集资金的使用与管理，提高募集资金使用效益，切实保 护投资者利益，根据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上海证券交易所科创板上市公司自律监管指引第 1 号-规范 运作》、等相关法律法规和规范性文件以及《上海益诺思生物技术股 份有限公司公司章程》的规定，结合公司实际情况，制订本办法。 第二条 本办法所称募集资金是指公司通过向不特定对象发行证 券（包括首次公开发行股票、配股、增发、发行可转换公司债券、发 行分离交易的可转换公司债券等）以及向特定对象发行证券向投资者 募集的资金，但不包括公司实施股权激励计划募集的资金。 第三条 公司董事、监事和高级管理人员应当勤勉尽责，督促公 司规范使用募集资金，自觉维护公司募集资金安全，不得参与、协助 或纵容公司擅自或变相改变募集资金用途。 第四条 募集资金限定用于公司对外披露的募集资金投向，公司 董事会应当制订详细的资金使用计划，做到资金使用规范、公开、透 明。 第五条 董事会应以实现股东利益最大化为原则，当募集资金出 1 ...